Abyssinia Biologics
Boston
About Abyssinia Biologics
Abyssinia is a preclinical stage biotech company focusing on soluble amyloid oligomers to treat, prevent and detect Alzheimer's disease.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $766.5K
- Funding stage: Seed
- Last round: Seed (Jan 2024)
- Website: aby-bio.com
- Phone: [email protected]
Industries & Categories
Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/abyssinia-biologics-98794 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.